Skip to main content

Table 2 Common aberrant regions between primary and its PDX tumor

From: Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation

GAINED REGIONS

    

Chr Name

Start

Stop

Aberration Size

N° of Probes

Chr 1

794595

15755378

14960791

582

chr2

165884672

239972470

74087806

2499

chr3

132814897

195420586

62605690

1960

chr10

76385906

76844343

458439

19

chr12

322142

33190977

32868841

1192

chr15

59862504

63866586

4004083

152

chr20

60606430

62701643

2095216

123

LOST REGIONS

    

Chr Name

Start

Stop

Aberration Size

N° of Probes

chr1

246042299

246655416

613118

25

chr3

18852871

32750279

13897409

382

chr4

8003753

8269985

266233

10

chr5

60785924

71460780

10674857

275

chr6

389423

26225376

25835955

858

chr7

73901713

73947170

45458

4

chr7

143425418

143432891

7474

3

chr7

153530377

153586460

56084

3

chr8

176452

22995207

22818758

751

chr8

39237438

39380654

143217

7

chr9

204193

28849141

28644949

888

chr14

63888769

105942876

42054108

1679

chr15

29212452

29253376

40925

4

chr15

34735949

34785082

49134

3

chr18

47738189

78010032

30271844

911

chr19

2936567

3027913

91347

4

chr22

23998465

24040236

41772

4